




Organic Preparations and Procedures International: The New Journal for Organic Synthesis

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/uopp20>

SYNTHESIS OF SUBSTANCES RELATED TO FLUTICASONE PROPIONATE

Jin Zheng ^a, Qinglin Lai ^a, Yiru Dai ^b, Qingjie Zhao ^a & Jingshan Shen ^a

^a Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, PR CHINA

^b Topharman Shanghai Co., Ltd., Shanghai, 201209, PR CHINA E-mail:

Published online: 18 Feb 2009.

To cite this article: Jin Zheng, Qinglin Lai, Yiru Dai, Qingjie Zhao & Jingshan Shen (2008) SYNTHESIS OF SUBSTANCES RELATED TO FLUTICASONE PROPIONATE, Organic Preparations and Procedures International: The New Journal for Organic Synthesis, 40:6, 566-571, DOI: [10.1080/00304940809458122](https://doi.org/10.1080/00304940809458122)

To link to this article: <http://dx.doi.org/10.1080/00304940809458122>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

5. J. Wu, W. Vetter, G. W. Gribble, J. S. Schneekloth, Jr., D. H. Blank and H. Gorls, *Angew. Chem. Int. Ed.* **41**, 1740 (2002).
6. (a) W. Vetter and J. Wu, *Chemosphere* **52**, 423 (2003); (b) E. L. Teuten, B. E. Pedler, A. N. Hangsterfer and C. M. Reddy, *Environ. Pollut.* **144**, 336 (2006); (c) E. L. Teuten, R. Saint-Louis, B. E. Pedler, L. Xu, E. Pelletier and C. M. Reddy, *Mar. Pollut. Bull.* **52**, 572 (2006); (d) W. Vetter, S. Gaul, D. Olbrich and C. Gaus, *Chemosphere* **66**, 2011 (2007); (e) E. L. Teuten and C. M. Reddy, *Environ. Pollut.* **145**, 668 (2007); (f) K. Pangallo, R. K. Nelson, E. L. Teuten, B. E. Pedler and C. M. Reddy, *Chemosphere* **71**, 1557 (2008).
7. (a) L. Fu and G. W. Gribble, *Synthesis*, 788 (2008); (b) L. Fu and G. W. Gribble, *Tetrahedron Lett.* **48**, 9155 (2007); (c) L. Fu and G. W. Gribble, *Tetrahedron Lett.* **49**, 3545 (2008).
8. (a) H. O. House and T. H. Cronin, *J. Org. Chem.* **30**, 1061 (1965); (b) R. Mueller, J. Yang, C. Duan, E. Pop, L. H. Zhang, T. Huang, A. Denisenko, O. V. Denisko, D. C. Oniciu, C. L. Bisgaier, M. E. Pape, C. D. Freiman, B. Goetz, C. T. Cramer, K. L. Hopson and J. H. Dasseux, *J. Med. Chem.* **47**, 5183 (2004).

SYNTHESIS OF SUBSTANCES RELATED TO FLUTICASONE PROPIONATE


Submitted by Jin Zheng,[†] Qinglin Lai,[†] Yiru Dai,[‡] Qingjie Zhao[†] and Jingshan Shen^{*†}
(03/27/08)

[†] Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Shanghai 201203, P. R. CHINA

[‡] Topharman Shanghai Co., Ltd., Shanghai 201209, P. R. CHINA


E-mail: jsshshen@mail.shcnc.ac.cn

Related substances or impurities of active pharmaceutical ingredients (API) are important issues in process development, manufacturing and quality control of pharmaceutical compounds. In addition to drug efficacy, there is a strong emphasis on the purity of final drug substances and it is necessary to do full characterization and identification of any impurities to ensure the drug safety in clinical trials.¹ Fluticasone propionate is widely used for the treatment of allergy and inflammatory disorders,²⁻⁴ and analysis and control of impurities are important to clinical safety. Gram-scale amounts of such impurities were required by quality control (QC) department as markers to locate the known related substances in fluticasone. The preparation of



Fluticasone Propionate

the impurities is also important to understand the possible mechanisms of their formation and thus helps to optimize the process and reduce their level in the API. We herein report the synthesis of three impurities **5**, **9**, **11** related to fluticasone propionate found in the course of our optimization of the preparation of fluticasone propionate (*Scheme 1*).



Reagents: a) i. CDCl₃; ii. H₂S; b) i. C₂H₅COCI/Et₃N; ii. Et₂NH; c) BrCH₂Cl; d) NaI; e) AgF; f) CH₃COS₃OCH₂CH₃.

Scheme 1

Impurity **5** is a new compound isolated during our process optimization. Impurity **9** had been synthesized⁶ in 22% yield from **1** as a biologically active compound used to treat allergy and immunoinflammatory disorder^{3,7} and compound **11** has been suggested as another possible impurity.^{5,11} However, as far as we know no synthetic details and spectral data of these three compounds related to fluticasone propionate (**5**, **9** and **11**)⁸ have been described and now we report their synthesis (*Scheme 1*).

Regioselective acylation of **1** with propionyl chloride gave **2** (91%) which was alkylated with bromochloromethane in *N,N*-dimethylacetamide to afford **3** in 61% yield. Reaction of **3** with sodium iodide led to the iodomethyl derivative **4** (84%) which was then treated with silver fluoride to give the **5**. Similarly, compound **9** was easily obtained via an analogous procedure in a yield higher (36%) than that previously reported⁶. Compound **1** was converted to compound **6** by using H₂S in DMF with CDI in 92% yield. Regioselective acylation of **6** with propionyl chloride gave **10** (91%)⁸.

EXPERIMENTAL SECTION

Melting points were determined on a WRR melting point apparatus and are uncorrected. Elemental analyses were performed on Elementar Vario EL. All reagents, solvents and compound **1** are commercially available and used as received. ¹H NMR spectra were obtained on a Bruker AMX-400/600 at 300 MHz using TMS as an internal standard. ¹³C NMR spectra were obtained from a Gemini-300 spectrometer in deuterated solvents with TMS as an internal standard at room temperature. The mass spectra were recorded on a Finnigan MAT-95/711 spectrometer.

6a,9a-Difluoro-11β-hydroxy-16α-methyl-3-oxoandrosta-17α-(propionyloxy)androsta-1,4-diene-17β-carboxylic Acid (2). A solution of compound **1** (396 mg, 1.0 mmol) and Et₃N (353 μL, 2.5 mmol) in CH₂Cl₂ (10 mL) at -5°C was treated dropwise with stirring with propionyl chloride (219 μL, 2.5 mmol) in CH₂Cl₂ (0.5 mL). After 1 h, the reaction mixture was diluted with 10 mL CH₂Cl₂, washed with water, 10% hydrochloric acid, water, and brine, dried, and evaporated. The solid residue was stirred in acetone (10 mL), and treated with Et₃NH (363 μL, 3.5 mmol) for 1 h then the solution was poured into 10% hydrochloric acid (20 mL) and ice (20 mL). The precipitate was collected and dried to give compound **2** as a white solid (411 mg, 91%), mp. 219-220°C, *lit.*¹⁰ mp. 217-218°C. The spectroscopic data correspond to those reported in literature.¹⁰

Chloromethyl-6a,9a-difluoro-11b-hydroxy-16a-methyl-3-oxoandrosta-17a-(propionyloxy)androsta-1,4-diene-17b-carboxylate (3). A solution of compound **2** (452 mg, 1.0 mmol) in DMA (2 mL) was stirred with NaHCO₃ (168 mg, 2.0 mmol) and bromochloromethane (325 μL, 5.0 mmol) for 40 h, diluted with EtOAc (10 mL), washed with 5% NaHCO₃ and water, dried, evaporated and crystallized to give compound **3** as a white solid (306 mg, 61%), mp. 239-241°C. ¹H-NMR (300 MHz, acetone-*d*₆): δ 7.28 (dd, *J* = 9.9, 1.5 Hz,

1H), 6.27 (dd, $J = 9.9, 1.8$ Hz, 1H), 6.21 (m, 1H), 5.93 (d, $J = 6.1$ Hz, 1H), 5.72 (d, $J = 6.1$ Hz, 1H), 5.62 (dddd, $J = 49.5, 11.8, 6.8, 1.8$ Hz, 1H), 4.39 (ddd, $J = 9.5, 3.7, 2.3$ Hz, 1H), 3.29 (m, 1H), 2.66 (m, 1H), 2.38 (q, $J = 7.5$ Hz, 2H), 2.34 (m, 1H), 2.22 (m, 2H), 1.89 (m, 2H), 1.62 (m, 1H), 1.61 (s, 3H), 1.31 (m, 1H), 1.12 (s, 3H), 1.07 (t, $J = 7.5$ Hz, 3H), 0.92 (d, $J = 6.9$ Hz, 3H). ^{13}C -NMR (100 MHz, acetone- d_6): δ 185.3, 173.5, 168.2, 162.8, 152.0, 129.8, 120.5, 101.1, 99.4, 86.4, 71.1, 70.0, 48.8, 43.7, 36.7, 36.2, 34.5, 34.3, 33.5, 33.0, 27.4, 23.2, 16.3, 16.2, 9.1.

HRMS(ESI) m/z Calcd for $\text{C}_{25}\text{H}_{31}\text{ClF}_2\text{O}_6$ $[\text{M}+\text{Na}]^+$ 523.1675. Found: 523.1669.

Anal. Calcd. for $\text{C}_{25}\text{H}_{31}\text{ClF}_2\text{O}_6$: C, 59.94; H, 6.24. Found: C, 60.07; H, 6.28

Iodomethyl-6 α ,9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxoandrosta-17 α -(propionyloxy)androsta-1,4-diene-17 β -carboxylate (4). Compound **3** (501 mg, 1.0 mmol) and NaI (1.5 g, 10 mmol) were refluxed in acetone (10 mL) for 7 h, EtOAc (7.5 mL) was added, and the solution was washed with water, 10% sodium thiosulfate, 5% NaHCO_3 , and water, dried, evaporated *in vacuo* and crystallized to give compound **4** as a white solid (497 mg, 84%), mp. 189–191°C. ^1H -NMR (300 MHz, acetone- d_6): δ 7.23 (dd, $J = 10.2, 1.5$ Hz, 1H), 6.27 (dd, $J = 10.2, 2.0$ Hz, 1H), 6.21 (m, 1H), 5.93 (d, $J = 6.1$ Hz, 1H), 5.72 (d, $J = 6.1$ Hz, 1H), 5.62 (dddd, $J = 48.9, 11.5, 6.7, 1.7$ Hz, 1H), 4.40 (ddd, $J = 9.8, 3.6, 2.5$ Hz, 1H), 3.27 (m, 1H), 2.65 (m, 1H), 2.38 (q, $J = 7.5$ Hz, 2H), 2.34 (m, 1H), 2.22 (m, 2H), 1.85 (m, 2H), 1.62 (m, 1H), 1.61 (s, 3H), 1.31 (m, 1H), 1.13 (s, 3H), 1.07 (t, $J = 7.5$ Hz, 3H), 0.92 (d, $J = 7.5$ Hz, 3H). ^{13}C -NMR (100 MHz, acetone- d_6): δ 185.2, 173.4, 168.3, 163.0, 151.9, 129.9, 120.5, 101.1, 99.3, 86.5, 71.4, 48.6, 43.8, 36.8, 36.2, 34.3, 33.8, 33.5, 33.1, 31.7, 27.5, 23.2, 16.3, 16.2, 9.1.

HRMS(ESI) m/z : Calcd for $\text{C}_{25}\text{H}_{31}\text{F}_2\text{IO}_6$ $[\text{M}+\text{Na}]^+$ 615.1031. Found: 615.1044

Anal. Calcd. for $\text{C}_{25}\text{H}_{31}\text{F}_2\text{IO}_6$: C, 50.69; H, 5.27. Found: C, 50.73; H, 5.32

Fluoromethyl-6 α ,9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxoandrosta-17 α -(propionyloxy)androsta-1,4-diene-17 β -carboxylate (5). Compound **4** (592 mg, 1.0 mmol) and AgF (634mg, 5.0 mmol) were stirred in the dark at room temperature in CH_3CN (10 mL) for 3 h. The reaction mixture was diluted with EtOAc (100 mL) and filtered. The filtrate was washed with water, dried, evaporated *in vacuo* and crystallized to give **5** as a white solid (402 mg, 83%), mp. 233–235°C. ^1H -NMR (300 MHz, acetone- d_6): δ 7.28 (dd, $J = 10.3, 1.6$ Hz, 1H), 6.27 (dd, $J = 10.3, 1.8$ Hz, 1H), 6.21 (m, 1H), 5.88 (dd, $J = 51.1, 2.2$ Hz, 1H), 5.62 (dd, $J = 50.9, 2.2$ Hz, 1H), 5.61 (m, 1H), 4.40 (ddd, $J = 9.8, 3.8, 2.4$ Hz, 1H), 3.30 (m, 1H), 2.70 (m, 1H), 2.39 (q, $J = 7.5$ Hz, 2H), 2.34 (m, 1H), 2.24 (m, 2H), 1.89 (m, 2H), 1.62 (m, 1H), 1.61 (s, 3H), 1.32 (m, 1H), 1.10 (s, 3H), 1.07 (t, $J = 7.5$ Hz, 3H), 0.92 (d, $J = 7.2$ Hz, 3H). ^{13}C -NMR (100 MHz, acetone- d_6): δ 185.1, 173.4, 168.4, 162.8, 151.7, 130.0, 120.5, 101.0, 99.3, 93.7, 86.5, 71.3, 48.8, 48.6, 43.7, 36.7, 36.2, 34.5, 34.3, 33.6, 33.1, 23.2, 16.3, 16.2, 9.1.

HRMS(ESI) m/z : Calcd for $\text{C}_{25}\text{H}_{31}\text{F}_3\text{O}_6$ $[\text{M}+\text{Na}]^+$ 507.1970. Found: 507.1951.

Anal. Calcd for $\text{C}_{25}\text{H}_{31}\text{F}_3\text{O}_6$: C, 61.97; H, 6.45. Found: C, 61.93; H, 6.38

6 α ,9 α -Difluoro-11 β ,17 α -dihydroxy-16 α -methyl-3-oxoandrosta-1,4-diene-17 β -carbothioic Acid (6). A solution of compound **1** (396 mg, 1.0 mmol) in DMF (10 mL) was treated with CDI

(324 mg, 2.0 mmol), and the mixture was stirred under nitrogen at room temperature for 4 h. Hydrogen sulfide was bubbled into the reaction mixture for 30 min. After 4 h the reaction mixture was poured into 2 mol/L HCl (10 mL) and ice (10 mL), the precipitate was collected and dried to give **6** as a white solid (380 mg, 92%) mp. 230–231°C, *lit.*⁸ mp. 230–232°C. The spectroscopic data correspond to those reported in literature.⁸

S-Iodomethyl-6 α ,9 α -difluoro-11 β ,17 α -dihydroxy-16 α -methyl-3-oxoandrosta-1,4-diene-17 β -carbothioate (8). A solution of compound **6** (412 mg, 1.0 mmol) in DMA (2 mL) was stirred with NaHCO₃ (168 mg, 2.0 mmol) and bromochloromethane (325 μ L, 5.0 mmol) for 40 h, diluted with EtOAc (10 mL), washed with 5% NaHCO₃ and water, dried, evaporated *in vacuo* to give crude compound **7** as a white solid (EIMS *m/z* 460 [M⁺]). The crude compound **7** and NaI (1.5 g, 10 mmol) were refluxed in acetone (10 mL) for 7 h, EtOAc (7.5 mL) was added, and the solution was washed with water, 10% sodium thiosulfate, 5% NaHCO₃, and water, dried, evaporated and crystallized to give compound **8** as a white solid (199 mg, 36%), mp. 218–220°C. ¹H-NMR (300 MHz, acetone-*d*₆): δ 7.27 (dd, *J* = 10.2, 1.5 Hz, 1H), 6.25 (dd, *J* = 10.2, 2.0 Hz, 1H), 6.20 (m, 1H), 5.62 (dddd, *J* = 48.8, 11.4, 6.7, 1.9 Hz, 1H), 4.52 (s, 2H), 4.35 (ddd, *J* = 10.6, 3.9, 2.1 Hz, 1H), 3.09 (m, 1H), 2.64 (m, 1H), 2.31 (m, 3H), 1.86 (m, 1H), 1.63 (m, 2H), 1.61 (s, 3H), 1.29 (m, 1H), 1.12 (s, 3H), 0.96 (d, *J* = 7.4 Hz, 3H). ¹³C-NMR (100 MHz, acetone-*d*₆): δ 201.3, 185.1, 163.0, 151.8, 129.9, 120.5, 92.4, 88.4, 86.6, 71.6, 49.6, 48.8, 44.4, 37.7, 36.1, 34.6, 34.4, 33.5, 30.1, 23.3, 16.8, 14.8.

HRMS(ESI) *m/z*: Calcd for C₂₂H₂₇F₂IO₄S [M+Na]⁺ 575.0540. Found: 575.0555.

Anal. Calcd. for C₂₂H₂₇F₂IO₄S: C, 47.83; H, 4.93. Found: C, 48.08; H, 4.91

S-Fluoromethyl-6 α ,9 α -difluoro-11 β ,17 α -dihydroxy-16 α -methyl-3-oxoandrosta-1,4-diene-17 β -carbothioate (9). Compound **8** (552 mg, 1.0 mmol) and AgF (634 mg, 5.0 mmol) were stirred in the dark at room temperature in CH₃CN (10 mL) for 3 h. The reaction mixture was diluted with EtOAc (10 mL) and filtered. The filtrate was washed with water, dried, evaporated and crystallized to give **9** as a white solid (364 mg, 82%), mp. 237–239°C. The spectroscopic data correspond to those reported in literature.⁶

6 α ,9 α -Difluoro-11 β -hydroxy-16 α -methyl-3-oxoandrosta-17 α -(propionyloxy)androsta-1,4-diene-17 β -carbothioic Acid (10). A solution of compound **6** (412 mg, 1.0 mmol) and Et₃N (353 μ L, 2.5 mmol) in CH₂Cl₂ (10 mL) at -5°C was treated dropwise with stirring with propionyl chloride (219 μ L, 2.5 mmol) in CH₂Cl₂ (0.5 mL). After 1 h the reaction mixture was diluted with CH₂Cl₂, washed with water, 10% hydrochloric acid, water, and brine, dried, and evaporated. The residue was stirred in acetone (10 mL), and treated with Et₃NH (363 μ L, 3.5 mmol) for 1 h then the solution was poured into 10% hydrochloric acid (20 mL) and ice (20 mL). The precipitate was collected and dried to give compound **10** as a white solid (427 mg, 91%), mp. 161–163°C, *lit.*⁸ mp. 161–164°C. The spectroscopic data correspond to those reported in literature.⁸

17,17'-(Trisulfanediyldicarbonyl)bis(6 α ,9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxoandrosta-1,4-diene-17 α -yl) Dipropionate (11)^{5,11}. Compound **10** (469 mg, 1.0 mmol) and

acetylenethoxytrisulfides (92 mg, 1.0 mmol) were refluxed in CCl_4 (3 mL) and CH_2Cl_2 (3 mL) for 8 h. the solution was evaporated and the residue was chromatographed on silica gel using CH_2Cl_2 - CH_3OH (100:2) to give **11** as a yellow solid (203mg, 42%), mp. 178-180°C. $^1\text{H-NMR}$ (300 MHz, acetone- d_6): δ 7.26 (dd, J = 10.3, 1.6 Hz, 2H), 6.26 (dd, J = 10.3, 2.0 Hz, 2H), 6.20 (m, 2H), 5.61 (dddd, J = 48.8, 11.5, 6.5, 1.7 Hz, 2H), 4.40 (m, 2H), 3.37 (m, 2H), 2.67 (m, 2H), 2.46 (q, J = 7.5 Hz, 4H), 2.34 (m, 2H), 2.22 (m, 4H), 1.97 (m, 4H), 1.62 (m, 2H), 1.61 (s, 6H), 1.39 (m, 2H), 1.12 (m, 12H), 0.99(d, J = 7.8 Hz, 6H). $^{13}\text{C-NMR}$ (100 MHz, DMSO- d_6): δ 192.1, 184.4, 172.5, 162.8, 151.8, 129.1, 119.4, 100.8, 96.1, 87.6, 69.6, 48.0, 47.8, 42.8, 36.6, 35.1, 33.5, 33.5, 30.7, 26.8, 22.7, 16.8, 16.1, 8.9.

HRMS (ESI) m/z Calcd for $\text{C}_{48}\text{H}_{58}\text{F}_4\text{O}_{10}\text{S}_3$ $[\text{M}+\text{Na}]^+$ 989.3026. Found: 989.3005.

REFERENCES

1. International Conference on Harmonisation (ICH-2), Document on Impurities in New Drug Substances.
2. L. Pereswetoff-Morath and A. Carlsson, *WO2006131737* (2006); *Chem. Abstr.*, **146**, 68699 (2006).
3. L. Voigtlaender and B. Voigtlaender, *DE102005023760* (2006); *Chem. Abstr.*, **145**, 500081(2006).
4. D. A. Lewis, B. J. Meakin and G. Brambilla, *US2006257324* (2002); *Chem. Abstr.*, **145**, 511665 (2006).
5. European Pharmacopoeia 5.0, Council of Europe 1627 (2005).
6. G. Cainelli, R. A. Umani, S. Aandri, M. Contento and G. Fortunato, *WO2004052912* (2004); *Chem. Abstr.*, **141**, 54528 (2004).
7. B. A. Ausspitz, B. B. Brasher, T. W. Chappell, M. G. Frank, D. Grau, E. R. Jost-Price, S. Lederman, P. Manivfasakam, N. Sachs and B. Smith, *WO2006138518* (2006); *Chem. Abstr.*, **146**, 93540 (2006).
8. G. H. Phillips, E. J. Bailey and B. M. Bain, *J. Med. Chem.*, **37**, 3717 (1994).
9. H. Kagami, H. Satsumabayashi and S. Motoki. *J. Org. Chem.*, **42**, 958 (1977).
10. D. J. Kertesz and M. Marx, *J. Org. Chem.*, **51**, 2315 (1986).
11. V. G. Gore, M. Gadakar, K. Pokharkar and V. Wakchure, *WO2007144668*; *Chem. Abstr.*, **148**, 55252 (2007).